Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A multi-disciplinary team of scientists, including Dr Claire Edwards from the Nuffield Department of Surgical Sciences, has been shortlisted to the final stages of Cancer Research UK's Grand Challenge – an ambitious series of £20m global grants tackling some of the toughest questions in cancer research.

The team, led by Professor Peter Croucher at the Garvan Institute of Medical Research in Sydney, Australia, involves researchers at the University of Oxford, Garvan, QIMR Berghofer Medical Research Institute and the University of Adelaide in Australia, as well as Israel’s Weizmann Institute of Science, the Babraham Institute (UK), Yale University (USA) and Washington University (USA).

The international collaboration, collectively called team InSIGHT (slaying the buried giant) aims to address the challenge of dormancy – when cancer returns after seemingly successful treatment due to dormant cancer cells that take refuge in other parts of the body. The team will focus on dormant breast cancer cells found in bones. Breast cancer is responsible for over 55,000 new diagnoses in the UK each year. Secondary breast cancer tumours are found in bones more than anywhere else in the body, indicating it is a preferred location for dormant breast cancer cells. Currently little is understood about treatment-resistant dormant cells, the team aims to examine them in fine molecular detail and hopefully uncover weaknesses that could help to beat more cancers for good.

The Reik group will primarily focus on changes to the cancer epigenome – the reversible chemical changes in cells that regulate gene activity throughout the genome. They will contribute their world-leading expertise in understanding large-scale epigenomics during development and disease. The group have developed techniques to study the epigenome of single cells, which can be used to uncover hidden variation within a group of cells. This has contributed to the discovery of several key mechanisms involved in epigenome reprogramming. Using these techniques, the team will examine epigenome reprogramming in cancer and attempt to identify rare markers that could be used to help detect dormant cells.

The InSIGHT team will receive seed-funding of up to £30,000 from Cancer Research UK to draft their full research proposal, and the winning proposal will be announced in autumn 2018.

The Grand Challenge award aims to revolutionise how we diagnose, prevent and treat cancer by providing international multi-disciplinary teams the freedom to try novel approaches, at scale, in the pursuit of life changing discoveries.

This is the second round of Cancer Research UK’s Grand Challenge award and last year four teams were awarded up to £20 million each.

Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: “Round two of Grand Challenge is proving to be incredibly inspiring and the ambitious applications reflect the quality of global researchers this initiative has attracted to beat cancer sooner. We’re delighted with the teams we’ve shortlisted and look forward to hearing more about how they plan to tackle the toughest challenges in cancer research.”

Dr Rick Klausner, chair of Cancer Research UK’s Grand Challenge advisory panel, said: “The challenges set for Grand Challenge have once again attracted some of the best researchers in the world. I’m looking forward to see how global collaboration could bring together diverse expertise, invigorate areas of research, and overcome barriers in ways that aren’t happening at this point in time.”

Similar stories

Professor Peter McCulloch receives NIHR Senior Investigator Award

Awards and appointments

We are delighted to announce that Professor Peter McCulloch of the Nuffield Department of Surgical Sciences has been awarded the title of NIHR Senior Investigator.

New Cochrane evidence explores treatment options for chronic ear disease

Publication Research

A new Evidently Cochrane blog post for World Hearing Day summarises seven recent reviews on medical treatments for infection and inflammation of the middle ear.

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

NDS project awarded Public Engagement Seed Funding 2020-21

Awards and appointments Public engagement

Seven projects from the Medical Sciences Division, including a project from the Nuffield Department of Surgical Sciences, have received funding in the 2020-21 round of the Public Engagement with Research Seed Fund for innovative projects to engage the public with medical research.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.